These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125 [TBL] [Abstract][Full Text] [Related]
27. Androgen deprivation modulates gene expression profile along prostate cancer progression. Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909 [TBL] [Abstract][Full Text] [Related]
28. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281 [TBL] [Abstract][Full Text] [Related]
29. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. Muralidhar V; Catalano PJ; Reznor G; Mahal BA; Choueiri TK; Sweeney CJ; Martin NE; Beard CJ; Chen YW; Nezolosky MD; Hoffman KE; Feng FY; Trinh QD; Nguyen PL J Natl Compr Canc Netw; 2016 Apr; 14(4):421-8. PubMed ID: 27059190 [TBL] [Abstract][Full Text] [Related]
30. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy. de Crevoisier R; Slimane K; Messai T; Wibault P; Eschwege F; Bossi A; Koscielny S; Bridier A; Massard C; Fizazi K Ann Oncol; 2010 Apr; 21(4):808-814. PubMed ID: 19825885 [TBL] [Abstract][Full Text] [Related]
31. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy. Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664 [TBL] [Abstract][Full Text] [Related]
32. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. Gupta M; Patel HD; Schwen ZR; Tran PT; Partin AW BJU Int; 2019 Feb; 123(2):252-260. PubMed ID: 29626845 [TBL] [Abstract][Full Text] [Related]
33. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer. Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880 [TBL] [Abstract][Full Text] [Related]
34. Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort. Inamoto T; Azuma H; Hinotsu S; Tsukamoto T; Oya M; Ogawa O; Kitamura T; Kazuhiro S; Naito S; Namiki M; Nishimura K; Hirao Y; Usami M; Murai M; Akaza H; J Cancer Res Clin Oncol; 2014 Jul; 140(7):1197-204. PubMed ID: 24676427 [TBL] [Abstract][Full Text] [Related]
35. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Pollack A; Kwon D; Walker G; Khor LY; Horwitz EM; Buyyounouski MK; Stoyanova R J Natl Cancer Inst; 2017 Feb; 109(2):1-8. PubMed ID: 28376214 [TBL] [Abstract][Full Text] [Related]
36. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616 [TBL] [Abstract][Full Text] [Related]
37. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Khor R; Duchesne G; Tai KH; Foroudi F; Chander S; Van Dyk S; Garth M; Williams S Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):679-85. PubMed ID: 22954770 [TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer. Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252 [TBL] [Abstract][Full Text] [Related]
39. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
40. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. Zelefsky MJ; Eastham JA; Cronin AM; Fuks Z; Zhang Z; Yamada Y; Vickers A; Scardino PT J Clin Oncol; 2010 Mar; 28(9):1508-13. PubMed ID: 20159826 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]